J Havla1, T Kümpfel, R Hohlfeld. Show Affiliations » 1. Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München, München, Germany.
Abstract
Entities: Disease
Mesh： See more » Administration, OralAntibodies, Monoclonal, Humanized/administration & dosageAntibodies, Monoclonal, Humanized/adverse effectsBrain/pathologyCombined Modality TherapyDiagnosis, DifferentialDose-Response Relationship, DrugDrug Administration ScheduleFingolimod HydrochlorideGlatiramer AcetateGlucocorticoids/administration & dosageGlucocorticoids/adverse effectsHumansImmunosuppressive Agents/administration & dosageImmunosuppressive Agents/adverse effectsInfusions, IntravenousInterferon-beta/administration & dosageInterferon-beta/adverse effectsMethylprednisolone/administration & dosageMethylprednisolone/adverse effectsMitoxantrone/administration & dosageMitoxantrone/adverse effectsMultiple Sclerosis, Chronic Progressive/diagnosisMultiple Sclerosis, Chronic Progressive/drug therapyMultiple Sclerosis, Relapsing-Remitting/diagnosisMultiple Sclerosis, Relapsing-Remitting/drug therapyNatalizumabPeptides/administration & dosagePeptides/adverse effectsPlasmapheresisPropylene Glycols/administration & dosagePropylene Glycols/adverse effectsPulse Therapy, DrugSphingosine/administration & dosageSphingosine/adverse effectsSphingosine/analogs & derivativesSpinal Cord/pathology
Substances： See more » Antibodies, Monoclonal, HumanizedGlucocorticoidsImmunosuppressive AgentsNatalizumabPeptidesPropylene GlycolsGlatiramer AcetateInterferon-betaMitoxantroneFingolimod HydrochlorideSphingosineMethylprednisolone
Year: 2012 PMID： 22492476 DOI： 10.1055/s-0032-1304927
Source DB: PubMed Journal: Dtsch Med Wochenschr ISSN： 0012-0472 Impact factor: 0.628